• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Hong Kong·Consumer Cyclical·0399.HK
Share

Starcoin Group Limited Stocks

HK$ 0.07Last Updated 01.06.2026

Issuer Rating

1/7
Performance

Poor

Risk

High

Recommendation

Sell

Market Cap

HK$ 21.05M

HK$ 0.07
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Innovative Pharmaceutical Biotech Limited, an investment holding company, engages in the trading of beauty equipment and products in the People's Republic of China and Hong Kong. The company operates in two segments, Trading of Beauty Products, and Research and Development. It is also involved in the securities investment; research, development, and commercialization of oral insulin products; distribution of bio-industrial products; and provision of genetic testing services. The company was formerly known as United Gene High-Tech Group Limited and changed its name to Innovative Pharmaceutical Biotech Limited in September 2015. Innovative Pharmaceutical Biotech Limited is headquartered in Sheung Wan, Hong Kong.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. Specifically, the stock is overpriced on P/FCF.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

29.07.2026 14:40

Shares of the company in which Trump's son has invested soared 20%. It will sell part of the business

29.07.2026 14:27

SK hynix shares fell 10% following the announcement of a record quarter. What spooked the market?

29.07.2026 13:30

"There's a stock exchange, but virtually no capital market": Why $13 billion Was Withdrawn from Kazakhstan

29.07.2026 12:40

Oninvest Index: Space-Sector Small-Cap Stocks Have Lost Their Half-Year Gains. What's Next?

29.07.2026 12:08

Russia has issued an arrest warrant for Telegram founder Durov under a terrorism-related charge

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026